- Home
- FLGC vs BLRX Comparison
FLGC vs BLRX Comparison
Compare FLGC & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- BLRX
- Stock Information
- Founded
- FLGC 2019
- BLRX 2003
- Country
- FLGC United States
- BLRX Israel
- Employees
- FLGC N/A
- BLRX N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- BLRX Health Care
- Exchange
- FLGC Nasdaq
- BLRX Nasdaq
- Market Cap
- FLGC 15.9M
- BLRX 15.3M
- IPO Year
- FLGC 2021
- BLRX 2011
- Fundamental
- Price
- FLGC $0.62
- BLRX $4.46
- Analyst Decision
- FLGC Buy
- BLRX Strong Buy
- Analyst Count
- FLGC 2
- BLRX 2
- Target Price
- FLGC $4.00
- BLRX $19.00
- AVG Volume (30 Days)
- FLGC 108.2K
- BLRX 49.8K
- Earning Date
- FLGC 08-11-2025
- BLRX 08-14-2025
- Dividend Yield
- FLGC N/A
- BLRX N/A
- EPS Growth
- FLGC N/A
- BLRX N/A
- EPS
- FLGC N/A
- BLRX N/A
- Revenue
- FLGC $53,260,000.00
- BLRX $22,340,000.00
- Revenue This Year
- FLGC N/A
- BLRX N/A
- Revenue Next Year
- FLGC N/A
- BLRX N/A
- P/E Ratio
- FLGC N/A
- BLRX N/A
- Revenue Growth
- FLGC N/A
- BLRX 91.68
- 52 Week Low
- FLGC $0.42
- BLRX $2.30
- 52 Week High
- FLGC $2.11
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- FLGC 53.08
- BLRX 53.15
- Support Level
- FLGC $0.62
- BLRX $4.47
- Resistance Level
- FLGC $0.72
- BLRX $4.74
- Average True Range (ATR)
- FLGC 0.05
- BLRX 0.30
- MACD
- FLGC 0.00
- BLRX -0.01
- Stochastic Oscillator
- FLGC 64.75
- BLRX 61.23
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.